Relief Therapeutics Holding (XSWX:RLF) Operating Income: CHF-8.58 Mil (TTM As of Jun. 2025)

What is Relief Therapeutics Holding Operating Income?

Relief Therapeutics Holding XSWX:RLF +4.90% 20 Operating Income is CHF-8.58 Mil as of Jun. 2025. GuruFocus rates XSWX:RLF with a GF Score™ of 20/100 and a GF Value™ of CHF6.28. The stock has 5 warning signs investors should review.

Relief Therapeutics Holding's Operating Income for the six months ended in Jun. 2025 was CHF-4.73 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2025 was CHF-8.58 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Relief Therapeutics Holding's Operating Income for the six months ended in Jun. 2025 was CHF-4.73 Mil. Relief Therapeutics Holding's Revenue for the six months ended in Jun. 2025 was CHF1.22 Mil. Therefore, Relief Therapeutics Holding's Operating Margin % for the quarter that ended in Jun. 2025 was -388.10%.

Relief Therapeutics Holding's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Relief Therapeutics Holding's annualized ROC % for the quarter that ended in Jun. 2025 was -27.35%. Relief Therapeutics Holding's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -393.87%.

Relief Therapeutics Holding (XSWX:RLF) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Relief Therapeutics Holding's annualized ROC % for the quarter that ended in Jun. 2025 is calculated as:

	ROC % (Q: Jun. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2024 )	+	Invested Capital (Q: Jun. 2025 ))	/ count )
=	-9.454 * ( 1 - 0.58% )	/	( (34.925	+	33.816)	/ 2 )
=	-9.3991668	/	34.3705
=	-27.35 %

where

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	53.224	-	3.593	-	( 15.08	-	max(0, 4.982	-	19.688	+	15.08	))
=	34.925

	Invested Capital		(Q: Jun. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	47.987	-	2.735	-	( 12.5	-	max(0, 3.753	-	15.189	+	12.5	))
=	33.816

Note: The Operating Income data used here is two times the semi-annual (Jun. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Relief Therapeutics Holding's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2024		Q: Jun. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-8.874	/	( ( (2.396 + max(-0.486, 0))	+	(2.11 + max(-1.586, 0)) )	/	2 )
=	-8.874	/	( ( 2.396	+	2.11 )	/	2 )
=	-8.874	/	2.253
=	-393.87 %

where Working Capital is:

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.437	+	1.042	+	1.537)	-	(3.593	+	0.852	+	0.056999999999999)
=	-0.486

	Working Capital		(Q: Jun. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.577	+	0.923	+	0.298)	-	(2.735	+	0.639	+	0.0099999999999998)
=	-1.586

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2025) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Relief Therapeutics Holding's Operating Margin % for the quarter that ended in Jun. 2025 is calculated as:

Operating Margin %	=	Operating Income (Q: Jun. 2025 )	/	Revenue (Q: Jun. 2025 )
	=	-4.727	/	1.218
	=	-388.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Relief Therapeutics Holding Operating Income Related Terms

Relief Therapeutics Holding Operating Income Historical Data

* Premium members only.

The historical data trend for Relief Therapeutics Holding's Operating Income can be seen below:

Relief Therapeutics Holding Operating Income Chart

Relief Therapeutics Holding Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Operating Income

Get a 7-Day Free Trial

-20.49

-34.61

-35.47

-19.78

-7.91

Relief Therapeutics Holding Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25
Operating Income	Get a 7-Day Free Trial															-11.56	-8.22	-4.05	-3.86	-4.73

20GF Score

Relief Therapeutics Holding SA XSWX:RLF

Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Relief Therapeutics Holding Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-8.58 Mil.

Frequently Asked Questions Learn more about Operating Income →

What does a Operating Income of CHF-8.58 Mil mean?

Relief Therapeutics Holding (XSWX:RLF) has a Operating Income of CHF-8.58 Mil as of Jun. 2025. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Relief Therapeutics Holding and its competitors.

Is Relief Therapeutics Holding's Operating Income too high?

Relief Therapeutics Holding's current Operating Income is CHF-8.58 Mil. Overall, Relief Therapeutics Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.

How does Relief Therapeutics Holding's Operating Income compare to KTTA and OSRH?

Relief Therapeutics Holding's Operating Income of CHF-8.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Operating Income for a Biotechnology company?

A good Operating Income depends on the Biotechnology industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Operating Income mean?

A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Relief Therapeutics Holding and its competitors. Relief Therapeutics Holding's current Operating Income is CHF-8.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Relief Therapeutics Holding stock overvalued right now?

Relief Therapeutics Holding (XSWX:RLF) has a current Operating Income of CHF-8.58 Mil. The stock's GF Value™ is CHF6.28, compared to a current price of CHF3.00 — trading 52.2% below its estimated fair value. The current Operating Income is CHF-8.58 Mil. Relief Therapeutics Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Operating Income calculated?

Operating Income is calculated from a company's financial statements. For Relief Therapeutics Holding (XSWX:RLF), the current Operating Income is CHF-8.58 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Relief Therapeutics Holding (XSWX:RLF) Overvalued in 2026?

Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued. The current stock price of CHF3.00 is trading 52.2% below its estimated GF Value™ of CHF6.28.

Key valuation signals for XSWX:RLF:

Operating Income: CHF-8.58 Mil
GF Value™: CHF6.28 vs. price of CHF3.00 (52.2% below fair value)
GF Score™: 20/100 with 5 warning signs

No single metric tells the full story. See the XSWX:RLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Relief Therapeutics Holding Business Description

Industry Healthcare Biotechnology

Comparable Companies KTTA OSRH LIMN LNAI LEXX PMN CASI ITRM TRAW VYNE VRTX REGN ASX:CSL XBRU:UCB XKRX:207940 XBRU:ARGX ALNY ONC INSM XKRX:068270

Address Avenue de Secheron 15, Geneva, CHE, 1202

Website https://www.relieftherapeutics.com

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.

20GF Score

Get the complete analysis for XSWX:RLF

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF3.00

Price

CHF6.28

GF Value

View XSWX:RLF Analysis

See Operating Income data for all stocks →